peptide,Qualitative Measure,Measurement Inequality,Quantitative measurement,Units,Allele Name,MHC allele class,Ref Type,Ref Date,Ref Title,Assay Method,Assay Group,Host Name,Description_Length,Normalized_QM,netmhcpan_ba_BAV,ann_BAV,smmpmbec_BAV,smm_BAV,mhcflurry_BAV,netmhcpan_ba_BAV_Normalized,ann_BAV_Normalized,smmpmbec_BAV_Normalized,smm_BAV_Normalized,mhcflurry_BAV_Normalized,VTAPERNet_BAV_Normalized,VTAPERNet_BAV
VVGAAGVGK,Positive,=,11230.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1380281737223408,59.83,147.74,102.33636812979309,117.57094257962468,48.52,0.6218492560705053,0.5383034808302579,0.5722402998646032,0.5594140847697237,0.641214821410046,0.36835402250289917,929.1492948112625
VVGACGVGK,Positive,=,29080.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0500908926704839,72.99,134.97,104.23894326174305,119.2065173132749,51.66,0.6034740885915133,0.5466586835158486,0.5705377991053692,0.5581372092002981,0.6354191662733601,0.34371495246887207,1213.008244445033
VVGASGVGK,Positive,=,12710.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.126586135521855,50.69,114.36,80.17334432591531,91.68536114619248,52.78,0.6371710630946423,0.5619733378194245,0.5947984349244542,0.5823978450193829,0.6334368203468832,0.28220903873443604,2359.8162986788275
VVGAVGVGK,Positive-High,=,5071.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2115094143761372,38.76,65.47,68.0816386199307,82.66087535038571,42.77,0.6619719285475261,0.6135233169723948,0.6099081291626562,0.5919744117900745,0.6528730235026693,0.39959409832954407,662.6578122913561
VVVGAAGVGK,Positive-High,=,7030.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1813194548017949,104.17,243.11,61.49361153274806,84.30435305540806,37.47,0.5705989477907696,0.4922711102383082,0.6193144458574241,0.5901548641036434,0.6651002897141998,0.38366055488586426,787.3368259377411
VVVGACGVGK,Positive,=,15630.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1074727069657454,122.12,278.8,89.50143530311811,102.52977397953616,40.12,0.5559054870107658,0.4796109004378503,0.5846259928880307,0.5720657935367819,0.6587846011213385,0.3252450227737427,1481.3353891276834
VVVGADGVGK,Positive,=,15030.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1110905205326742,194.2,429.98,105.88391726063614,115.57130041198332,46.96,0.5130317445183769,0.4395690432293829,0.5690906734600202,0.5609995386017606,0.6442352075674126,0.3254696726799011,1477.7391356362527
VVVGARGVGK,Positive,=,46140.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.0074255451979363,162.14,308.51,90.95571663684504,103.71701280761008,44.33,0.5297075387495429,0.4702521523948814,0.5831363047237008,0.5710017305622606,0.6495619827792413,0.35315993428230286,1095.1713308480169
VVVGASGVGK,Positive,=,10230.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1466479611463769,79.28,213.1,53.19000118548209,73.4260219860633,37.79,0.5958340573094214,0.5044481136152221,0.632721639336392,0.6029236197978984,0.6643143304891337,0.3955666720867157,692.1720803498803
VVVGAVGVGK,Positive-High,=,6954.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1823240661673129,68.99,137.28,46.113703199347285,71.2606861926609,35.83,0.6086831490199263,0.5450902498777108,0.6459160202204559,0.6056901835316537,0.6692367036325164,0.39382052421569824,705.3735555746848
TVLEFILQK,Positive,,2.2,nM,HLA-A*11:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9271281407401551,7.22,9.68,8.433930152776446,9.644950431350724,21.78,0.8172924711633792,0.7901933069590426,0.8029291527408141,0.7905285628357432,0.7152444313998492,0.7945382595062256,9.235460509404536
